Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

46.97 +0.76 (+1.64%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,130,379
Open	47.38
Bid (Size)	45.70 (300)
Ask (Size)	47.71 (300)
Prev. Close	46.21
Today's Range	45.92 - 47.43
52wk Range	14.79 - 62.32
Shares Outstanding	41,151,111
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% ↗

June 27, 2026

This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.

Via The Motley Fool

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally ↗

June 27, 2026

Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains.

Via The Motley Fool

Performance

52-Week Range 24.6% below 52-week high

46.97

14.7952W Low 62.3252W High

1 Week 1.0% below 1-week high

44.191W Low 47.431W High

Enliven Therapeutics, Inc. - Common Stock (ELVN) traded between $14.79 and $62.32 over the past 52 weeks and last traded at $46.97, 24.6% below its 52-week high. Over the past week it ranged between $44.19 and $47.43.

Past 12 Months

+2.1%

-20.4%

-6.1%

+20.6%

+202.3%

+135.8%

1W +$0.96

1M -$12.04

3M -$3.04

6M +$8.03

YTD +$31.43

1Y +$27.05

ELVN was +135.8% over the past year, +20.6% over six months, +202.3% year to date, +2.1% in the last week.

12 Months vs Market

ELVN

+135.8%

DIA

+9.9%

SPY

+15.0%

QQQ

+23.7%

IWM

+15.4%

Over the past 12 months ELVN returned +135.8% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.02× 3-mo avg

Today 1,130,379 3-mo avg 1.1M

1.1M

1.4M

1.1M

1.2M

YTD

1.3M

1.1M

ELVN most recently traded 1,130,379 shares against a 3-month average daily volume of 1.1M.

More News

Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? ↗

June 24, 2026

Via The Motley Fool

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. ↗

June 01, 2026

Via The Motley Fool

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

Via The Motley Fool

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

Via The Motley Fool

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million ↗

March 28, 2026

Via The Motley Fool

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k ↗

February 01, 2026

Via The Motley Fool

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

January 12, 2026

From Equity Insider

Via GlobeNewswire

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗

January 08, 2026

Via Stocktwits

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗

January 08, 2026

Via Stocktwits

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI

December 15, 2025

Via TokenRing AI

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

Via The Motley Fool

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

Via The Motley Fool

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

Via The Motley Fool

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 15, 2025

Via Chartmill

Enliven Posts Loss Beat and Cash Surge ↗

August 13, 2025

Via The Motley Fool

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

July 02, 2025

Via Benzinga

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗

June 23, 2025

Via Stocktwits

Frequently Asked Questions

Is Enliven Therapeutics, Inc. - Common Stock publicly traded?

Yes, Enliven Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Enliven Therapeutics, Inc. - Common Stock trade on?

Enliven Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Enliven Therapeutics, Inc. - Common Stock?

The ticker symbol for Enliven Therapeutics, Inc. - Common Stock is ELVN on the Nasdaq Stock Market

What is the current price of Enliven Therapeutics, Inc. - Common Stock?

The current price of Enliven Therapeutics, Inc. - Common Stock is 46.97

When was Enliven Therapeutics, Inc. - Common Stock last traded?

The last trade of Enliven Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET

What is the market capitalization of Enliven Therapeutics, Inc. - Common Stock?

The market capitalization of Enliven Therapeutics, Inc. - Common Stock is 1.93B

How many shares of Enliven Therapeutics, Inc. - Common Stock are outstanding?

Enliven Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.